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Abstract
Background: Covalent linkage of ubiquitin regulates the function and, ultimately, the degradation of many proteins by the
ubiquitin-proteasome system (UPS). Given its essential role in protein regulation, even slight perturbations in UPS activity
can substantially impair cellular function.
Methodology/Principal Findings: We have generated and characterized a novel transgenic mouse model which expresses
a previously described reporter for UPS function. This UPS reporter contains a degron sequence attached to the C-terminus
of green fluorescent protein, and is predominantly expressed in neurons throughout the brain of our transgenic model. We
then demonstrated that this reporter system is sensitive to UPS inhibition in vivo.
Conclusions/Significance: Given the obstacles associated with evaluating proteasomal function in the brain, our mouse
model uniquely provides the capability to monitor UPS function in real time in individual neurons of a complex organism.
Our novel mouse model now provides a useful resource with which to evaluate the impact of aging, as well as various
genetic and/or pharmacological modifiers of neurodegenerative disease(s).
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Introduction
The ubiquitin-proteasome system (UPS) regulates the degrada-
tion of numerous regulatory proteins that control signal transduc-
tion, cell cycle progression and differentiation, as well as apoptotic
pathways [1]. Ubiquitin ligases covalently link ubiquitin polypep-
tide chains to proteins, marking those proteins as substrates for the
proteasome and allowing for targeted and selective degradation. In
addition to degrading regulatory proteins, the UPS also degrades
misfolded and damaged proteins, thus collectively implicating the
UPS in a wide range of conditions, including neurodegenerative
diseases, cancer, inflammation, and autoimmunity [2,3].
The proteasome is a large, multisubunit complex containing a
common proteolytic core, the 20S proteasome, which is composed
of 28 subunits arranged in four, heptameric rings. The two outer
rings are each composed of seven alpha-type subunits (a1–a7),
while the two inner rings each contain seven beta-type subunits
(b1–b7). The proteolytic activity is enclosed within the inner rings,
with only the b1, b2, and b5 subunits possessing caspase-like,
trypsin-like, and chymotrypsin-like cleavage specificity, respective-
ly [4,5]. The activity of the 20S proteasome is modulated by a
variety of regulators, including the 19S/PA700 complex, PA200,
as well as PA28 a/b and PA28c [6–8]. The most common
regulator, the 19S/PA700 complex, contains six AAA-family
ATPases and is capable of binding both ends of the 20S
proteasome in an ATP-dependent manner, forming the 26S
proteasome, which is involved in the degradation of ubiquitinated
proteins [9–11]. Given that only the 19S/PA700 complex
possesses ATPase activity and binds to polyubiquitin chains,
alternative regulators of the 20S proteasome are believed to
modulate ubiquitin-independent functions of the proteasome.
A diverse group of neurological disorders that are characterized
by an accumulation of ubiquitinated proteins (reviewed in [12]),
suggesting that UPS dysfunction is likely to play a prominent role
in the pathogenesis of neurodegenerative diseases. UPS impair-
ment has been reported in aging [13], brain ischemia [14,15],
Huntington’s disease (HD) [16–19], Cruetzfeldt-Jakob disease
(CJD), Alzheimer’s disease (AD) [20–23], Amyotrophic Lateral
Sclerosis (ALS) [24], and Parkinson’s disease (PD) [25–30].
Utilizing an innovative approach, Bedford and colleagues
established a compelling link between dysfunction of the 26S
proteasome and the development of a-synuclein neuropathology
[31]. By genetically ablating a critical 19S/PA700 subunit (Rpt2/
PSMC1) in the forebrain, and thus preventing formation of the
26S proteasome, Bedford and colleagues reveal that loss of 26S
proteasome activity leads to synuclein and ubiquitin-positive
inclusions in neurons of the forebrain, in addition to a learning
deficit and progressive degeneration of forebrain regions. Intrigu-
ingly, as knockdown of Rpt2/PSMC1 expression leads to a specific
impairment of 26S proteasome activity, while activity of the 20S
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attributed to dysfunction of the 26S proteasome [31].
We have now generated a mouse model which will facilitate the
identification of suitable targets in neurodegenerative diseases in
which UPS impairment has been implicated. Development of
therapies against these targets relies on our ability to pinpoint the
exact stage of disease in which proteasome impairment contributes
to the pathogenesis. To this end, we have engineered a transgenic
mouse expressing a reporter (GFPm) sensitive to perturbations in
UPS function as demonstrated by Bence and colleagues [32]. In
contrast to other transgenic mouse models expressing UPS
reporters throughout the body [32,33], GFPm expression in our
model is controlled by the mouse prion promoter (MoPrP). Use of
the MoPrP for this UPS reporter system largely targets transgenic
expression to neurons, providing an ideal model to evaluate the
role of proteasome function in neuronal cell biology. In this report,
we describe the development and characterization of this model,
and determine that aging alone does not alter neuronal GFPm
expression in our mouse model.
Results
GFPm protein and RNA is expressed throughout the brain
in 2-month mice
The GFP-CL1 reporter proteasome substrate (GFPm) was
utilized to generate our transgenic model, termed Degron mice
[34]. Briefly, GFPm consists of a short degron sequence fused to
the COOH end of the green fluorescent protein sequence, causing
rapid ubiquitination and proteasomal degradation. High expres-
sion levels of this reporter, previously described by Bence and
associates [32], are well tolerated in mammalian cells, and the
system is very sensitive to the effects of proteasome inhibition.
Using western-blotting and qRT-PCR to evaluate regional
GFPm protein and mRNA transgene expression levels respectively
in the Degron model, GFP is most highly expressed in cortical,
subcortical, hippocampal, and cerebellar regions (see Figure 1A–B,
I). Although the mRNA levels of GFP are relatively high in the
spinal cord, GFP protein expression in the spinal cord is very low
in comparison to other regions of the brain. Although native GFP
fluorescence is preserved in free-floating tissue sections, it is
difficult to detect GFP without antibody-mediated amplification of
the GFP signal given the low level of GFPm expression under
conditions when proteasomal function is not impaired. Using
immunohistochemical techniques, we were able to detect GFP in
the GFPm transgenic mice (Figure 1D–E, G–H), while specificity
of the immunolabeling was demonstrated by the lack of
immunoreactivity in non-transgenic mice (Figure 1C, F).
Primary neuronal cultures from GFPm mice are sensitive
to proteasomal inhibition
To verify the sensitivity of the GFPm reporter to proteasomal
inhibition, as well as to monitor the kinetics of GFPm induction,
primary hippocampal neurons generated from GFPm mice were
treated with 5 mM MG132, a proteasomal inhibitor, and harvested
at various time points after treatment (Figure 2A). As shown in
Figure 2A, increased GFPm protein levels are first observed at
12 hours, and maximal induction is observed following 24 hours
of exposure to 5 mM MG132. In addition, primary hippocampal
neurons from GFPm mice exhibit a dose-dependent induction of
GFPm when exposed to various concentrations of MG132
(0.1 mM–10 mM) for 24 hours (Figure 2B). Upregulation of GFPm
is coincident with increased ubiquitination following proteasomal
inhibition (Figure 2C), confirming the physiological relevance of
GFPm. Upregulation of GFPm in response to proteasomal
inhibition is also observed in primary hippocampal neurons using
confocal microscopy (Figure 2D=untreated, 2E=5 mM MG132
for 24 hours). We observed no difference in GFPm mRNA levels
between MG132-treated and untreated cells, confirming that the
increase in GFPm protein expression is due to a decrease in
proteasome-dependent degradation and not influenced by trans-
lational changes (data not shown).
GFPm mice are sensitive to proteasomal inhibition in vivo
To validate the GFPm reporter in vivo, we performed stereotaxic
injections of the proteasomal inhibitor MG132 into the cortices of
GFPm mice. Confirming our observations from primary neuronal
cultures, injection of MG132 led to a prominent increase in
cortical GFPm expression (Figure 3). In addition, given the extent
of GFPm upregulation in the MG132-injected mice, it was possible
to detect GFPm without antibody-mediated amplification of the
GFP fluorescent signal (Figure 3B–C). We detected only minimal
native GFP fluorescence in vehicle-injected (Figure 3A) and
uninjected controls (data not shown).
Effect of aging on GFPm protein and RNA expression
Given that aging has been reported to lead to UPS impairment
[13], we evaluated GFP protein (Figure 4; Figure S1) and mRNA
expression (Figure 5) in aged cohorts of Degron mice to determine
if aging alone would lead to an increase in GFP expression.
Surprisingly, as demonstrated in Figure 4, there was no change in
GFP protein expression between the ages of 6 to 18 months in the
cortex (F=0.243, p=0.788), hippocampus (F=3.092, p=0.075),
midbrain (F=2.598, p=0.108), or cerebellum (F=3.377,
p=0.062), which is consistent with results from immunohisto-
chemical studies on aging GFPm mice (Figure S1). In addition,
there was no observed difference in GFP accumulation with age
between male and female GFPm mice. As shown in Figure 5, there
was also no effect of aging on regional GFPm mRNA expression
(cortex, F=0.963, p=0.409; hippocampus, F=0.831, p=0.456;
cerebellum, F=0.265, p=0.771; midbrain, F=0.22, p=0.806),
indicating that aging alone does not significantly impair protea-
somal function in our mouse model.
Discussion
In this report, we describe the development, characterization,
and validation of our novel UPS reporter transgenic mouse model.
In contrast to earlier reports [13], we show that aging is not
associated with proteasome impairment in our mouse model,
though it is possible we may observe UPS dysfunction in mice aged
beyond 18 months [13]. However, our finding is consistent with a
recent study by the Dantuma lab using a transgenic mouse
expressing a different UPS reporter substrate [24]. Specifically,
the Dantuma group employed a model expressing a mutant form of
ubiquitin (G96V) fused to the N-terminus of GFP, which cannot be
cleaved and is instead polyubiquitinated on both the lysine 29 and
48 residues and targeted for proteasome-mediated degradation
[24,35]. Given that two different UPS reporter substrates do not
exhibit a significant accumulation with age, it is possible that
previous work evaluating proteasome activity and subunit expres-
sion in mouse brain homogenates does not accurately reflect UPS
function in vivo [13], making models such as ours valuable in
elucidating the in vivo roles of the UPS. Additionally, the recent
demonstration that specific inhibition of the 26S proteasome leads
to a neurodegenerative phenotype [31], as well as the finding that
neuronsand glia display different basal levels of UPSactivity[36], in
vivo models expressing UPS reporters are becoming increasingly
more valuable. These recent studies also highlight the major
Aging and UPS Function
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brain homogenates utilizing enzymatic assays, which do not
discriminate between 26S versus 20S proteasomes, and also cannot
differentiate between various cell types.
The utility of UPS reporter mice has also increased in parallel
with the number of neurodegenerative diseases being linked to
UPS dysfunction, making it somewhat of a common theme
associated with neurodegeneration. For example, soluble Ab
oligomer formation and impaired proteasomal function are
observed concomitantly in the triple transgenic mouse model of
AD; however, proteasome activity is restored when soluble Ab
oligomers are converted into insoluble aggregates [23]. This
suggests that soluble oligomeric Ab species, and not the
monomeric or fibrillar form of Ab, inhibits proteasomal activity
[23]. UPS impairment has also been observed in cell culture and
animal models overexpressing mutant huntingtin protein [16–
19,34,37–39], and consistent with data proposing a protective
effect of aggregation due to sequestration of toxic species,
treatment with a compound that increases inclusion formation
prevents huntingtin-mediated proteasome inhibition [19]. How-
ever, the lack of GFP accumulation in an HD mouse model (R6/2)
crossed to our GFPm mice may be indicative of a complex
relationship between overexpression of mutant polyglutamine
proteins and UPS function [40]. Importantly for prion disorders
such as CJD, the abnormal prion conformer (PrPsc) inhibits the
26S proteasome in vitro, while either preincubation with an
oligomer antibody or heat denaturation of PrPsc alleviated this
inhibitory effect [22]. These findings indicate that a specific
conformation of an oligomeric PrPsc intermediate mediates the
proteasomal inhibitory effect [22]. Proteasome activity was also
significantly decreased in both cells exposed to prion-infected
mouse brain homogenates and in brain regions exhibiting
Figure 1. GFPm protein and RNA is expressed throughout the brain. A) Representative WB showing regional GFPm expression in a 2-month
old GFPm+/2mouse. B) Quantification of WB data performed by calculating GFP O.D. on brain regions from 4 mice heterozygous for GFPm transgene,
and normalizing values to GAPDH. A calibrator sample was included on each gel to compare protein expression across gels. C–E) Confocal
microscopy of GFP immunoreactivity in nontransgenic cortex (C), and the cortex (D) and brainstem (E) from a 2-month old GFPm+/2mouse
(green=GFP, red=MAP2). F–H) Lack of GFP immunoreactivity in nontransgenic cortex (F), compared to specific GFP labeling in cortex (G) and
brainstem (H) of a 2-month old GFPm+/2mouse. I) Bar graph depicting quantification of regional mRNA expression from 4 heterozygous 2-month old
GFPm mice. (Ctx=cortex, Sub=subcortex, Hipp=hippocampus, MID=midbrain, BS=brainstem, Cb=cerebellum, SC=spinal cord; error bars=SEM).
doi:10.1371/journal.pone.0005888.g001
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5 mM MG132 is time dependent, with maximal induction observed at 24 hours. Synaptophysin was used as an endogenous loading control. B) GFPm
reporter is dose-dependently upregulated by 24 hours of MG132 treatment. C) Accumulation of GFPm reporter is coincident with increased
ubiquitination in the presence of MG132. D, E) Confocal microscopy of D=untreated and E=5 mM MG132 for 24 hrs (red=MAP2, blue=DAPI,
green=GFP).
doi:10.1371/journal.pone.0005888.g002
Figure 3. GFPm mice are sensitive to proteasomal inhibition in vivo. A) Without antibody-mediated amplification, little GFP
immunofluorescence is observed in cortical neurons near injection site of vehicle-injected control. B, C) In contrast, GFP immunofluorescence is
easily detectable and significantly upregulated in cortical neurons near injection site of MG132-injected mouse. Scale bar, 20 mm.
doi:10.1371/journal.pone.0005888.g003
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finding establishes a solid link between UPS impairment and
neurodegeneration associated with prion infection [22].
In regard to the link between UPS function and PD, multiple
publications have consistently reported greater proteasomal
impairment in the presence of aggregated a-synuclein in
comparison to its monomeric counterpart [41–43]. Although both
monomeric and aggregated a-synuclein have been shown to bind
the S69/TBP1 (Tat binding protein 1) subunit of the 19S/PA700
proteasome complex [42,44], only aggregated a-synuclein inhibits
ubiquitin-dependent and independent 26S proteasomal activity
[42]. Zhang and colleagues have demonstrated that a-synuclein
protofibrils inhibit the ubiquitin-independent degradation of
unstructured proteins by the 26S proteasome, though monomers
and dimers have no effect on the proteolysis of these substrates
[43]. In contrast, ubiquitin-dependent 26S proteasome activity is
slightly inhibited by monomeric and dimeric a-synuclein, while
protofibrillar a-synuclein potently inhibits the degradation of
Figure 4. No effect of aging on GFPm protein expression. Representative WB showing GFPm expression in cortex (Ctx), cerebellum (Cb),
midbrain (MID), and hippocampus (Hipp) from 6 to 18 months of age in heterozygous GFPm mice. Quantification of GFP O.D. was normalized to actin
to control for protein loading (each bar represents average GFP expression for n=6 mice [3 males, 3 females] at each time point, with error bars
depicting SEM).
doi:10.1371/journal.pone.0005888.g004
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bind the 19S/PA700 regulatory complex of the 26S proteasome,
as well as p21 (an unstructured proteasomal substrate) and K48-
linked polyubiquitin chains, it is proposed that a-synuclein
protofibrils inhibit 26S proteasome activity by interfering with
substrate translocation into the proteasome core, achieved through
direct interactions with the proteasome, as well as through the
sequestration of proteasomal substrates [43,45].
The GFPm UPS reporter mice described in this report provide a
novel resource with which to monitor the activity of the 26S
proteasome in vivo. A number of mouse models are available for
the neurodegenerative diseases in which UPS dysfunction has been
implicated. Crossing our Degron model with these neurodegen-
erative disease models, such as those for AD, will allow a unique
opportunity to directly follow the UPS impairment in relation to
neuropathological, biochemical, and behavioral features of the
model system. Such studies should help investigators understand if
and when the UPS plays a key role in disease pathogenesis.
Ultimately, such findings with our transgenic mouse model could
be utilized to identify key therapeutic timepoints in the disease
process, and to develop and screen therapeutic agents for the
potential to modulate UPS function at these timepoints.
Materials and Methods
Generation of GFPu construct/mice
To generate transgenic mice carrying the GFPm reporter
(described in [34]), the GFP-CL1 sequence was cloned into the
EcoR1 site of the mouse prion promoter construct [46]. The
construct cDNA was linearized with NotI, gel purified, and injected
into the pronuclei of fertilized eggs harvested from C57BL6/
DBA2/SW mice. Founder mice were bred to C57BL6 mice, and
progeny were screened at 3 weeks of age for integration of the
transgene using PCR and dot blotting analysis of genomic DNA
obtained from tail biopsies. 10 founder lines were expanded for
further characterization, and the founder line with the highest
level of expression was then used for all subsequent experiments.
Genotyping/GFP primers
To genotype mice, tail biopsies from 3 week old mice were
digested overnight at 55uC in Direct PCR Tail lysis buffer
(Qiagen) and proteinase K (Qiagen). Samples were then cooled to
room temperature, and PCR performed using GFP specific
primers (59GTG ACT CGA GAG ATC CGC TAG CGC TAC C
39) and (59 CAC CTT GAT GCC GTT CTT CT 39) detecting a
0.5 kB GFP band, against an internal 0.3 kB b-actin control (59
CGG AAC CGC TCA TTG CC 39) and (59 ACC CAC ACT
GTG CCC ATC TA 39). Tail DNA combined with dH2O, 106
PCR buffer (Qiagen), Q solution, each of the four primers, dNTPs,
and Taq (5 U/ml; Qiagen). DNA samples were then denatured for
4 minutes at 94uC using an Eppendorf mastercycler (epgradient S
model), undergo 3 cycles of 94uC for 15 seconds, 65uC for
30 seconds, and 72uC for 45 seconds, 10 cycles of 94uC for
15 seconds, 65uC for 30 seconds, and 72uC for 30 seconds, 20
cycles of 94uC for 15 seconds, 60uC for 30 seconds, and 72uC for
45 seconds, before a final 72uC extension step for 10 minutes.
Primary neuronal culture
For primary neuronal cultures, hippocampi from postnatal day
2 mouse pups were removed and stored at 4uC in HIBERNA-
Figure 5. No effect of aging on GFPm RNA expression. Regional GFPm mRNA expression was evaluated using GAPDH as an endogenous
loading control for each sample, and the lowest expressing sample for each region used as the calibrator sample for that respective brain region.
Samples were loaded in quadruplicates, and an n=6 mice used to determine RNA expression at each time point. Quantification of relative mRNA
expression revealed no effect of aging in any of the brain regions evaluated (cortex, F=0.963, p=0.409; hippocampus, F=0.831, p=0.456;
cerebellum, F=0.265, p=0.771; midbrain, F=0.22, p=0.806).
doi:10.1371/journal.pone.0005888.g005
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TM A media without calcium (BrainBits), supplemented with
B27 (Invitrogen), 0.5 mM GMAX (GIBCO), and gentamicin
(GIBCO). Excised hippocampi were digested in papain (2 mg/
mL; Fisher Scientific), triturated with a Pasteur pipet (bore size
0.8–1 mM), centrifuged to collect cell pellet, and resuspended in
Neurobasal A (Invitrogen), supplemented with B27, GMAX,
gentamicin, and bFGF (Invitrogen). Following determination of
cell number, neurons were plated on poly-D-lysine-coated
coverslips within 24-well plates for immunocytochemical studies
(seeded at a density of 2.5610
4 cells/coverslip), or seeded on poly-
D-lysine coated 6-welll plates for immunoblotting at a seeding
density of 2.5610
5 cells/well.
Mouse sacrifice/harvest
For immunohistochemical studies, mice were terminally anes-
thetized with sodium pentobarbital (i.p. 45–80 mg/kg), and when
unresponsive to toe pinch, a longitudinal incision was made over
the sternum, the diaphragm and ribs were cut, and the sternum
peeled back to expose the heart. A 25-gauge butterfly needle
attached by tubing to a perfusion pump was placed in the left
ventricle, and an incision made in the right atrium. The mice were
then transcardially perfused with saline (2.25 mL/min for
5 minutes until all blood was flushed from the system), followed
by fixative (4% paraformaldehyde; approximately 2.25 mL/min
for 15 minutes). Brains and spinal cords were then removed and
placed in 4% paraformaldehyde for 24 hours, and cyropreserved
in 30% sucrose until sectioning.
For regional protein and mRNA analysis, mice were sacrificed by
CO2 asphyxiation, and brains were rapidly removed and both
halves dissected on ice into 6 regions (cortex [CTX], subcortex
[SUB; includes striatum, thalamus, and hypothalamus], hippocam-
pus [HIPP], midbrain [MID], brainstem [BS], cerebellum [CB]).
Spinal cords were also excised, and all samples frozen on dry ice.
Immunohistochemistry/immunofluorescence and
confocal microscopy
Fixed brains were sectioned at 40 microns on a sliding
microtome (Leica SM2400), and stored in 0.12 M PBS with
0.02% sodium azide. Free-floating sections were washed in
0.05 M PBS with 0.02% triton X (PBS-Tx), blocked for 1 hour
in 10% normal goat serum (PBS-Tx), and incubated overnight in
anti-MAP2 (1:500, Sigma-Aldrich) or anti-GFP (1:100, Chemicon)
diluted in 1% normal goat serum (PBS-Tx). On the following day,
sections were washed in PBS-Tx, incubated for 1 hour in goat
anti-rabbit Alexa Fluor 568 (1:1000, Molecular Probes) or goat
anti-mouse Alexa Fluor 488 (1:1000, Molecular Probes) diluted in
1% normal goat serum (PBS-Tx). Sections were then washed in
PBS-Tx, incubated for 10 minutes in Hoescht 33258 (1:10000,
Invitrogen) diluted in PBS-Tx. Sections were again washed in
PBS-Tx, and then mounted onto Superfrost plus microscope slides
(Fisherbrand). After sections were dry, slides were coverslipped
with Fluoromount G (Southern Biotech). The depicted GFP
immunofluorescence from the MG132-stereotaxic injections into
the cortex of GFPm mice did not require antibody amplification.
Immunoblotting procedures
Each of the 6 sub-dissected regions from the left hemisphere and
the spinal cord were weighed and homogenized in 106volume of
homogenate buffer (50 mM Tris-HCl [pH 7.4], 300 mM NaCl,
5 mM EDTA, 1% Triton-X-100, 1% SDS, 1 mM PMSF,
protease inhibitor cocktail, phosphatase inhibitors I and II [Fisher
Scientific]). Following sonication, samples were centrifuged at
16,000 g for 15 minutes, and a BCA protein assay (Thermo
Scientific) performed on the supernatant. 30 mg of protein from
each sample was diluted in dH2O, 26 tris-glycine SDS sample
buffer (Invitrogen), and 5% b-mercaptoethanol (Sigma-Aldrich),
and heat-denatured for 5 minutes at 95uC. Samples were run on
4–20% tris-glycine gels (Invitrogen), and transferred to PVDF
membrane (Millipore). Membranes were blocked in 5% milk in
TBS/0.1% Triton-X-100, and incubated overnight in anti-GFP
(1:2000; Invitrogen), anti-actin (1:10,000; Sigma), or anti-GAPDH
(1:10,000; BioSource) at 4uC. Membranes were incubated in
HRP-conjugated secondary antibodies (1:5000; Jackson Immuno)
for 1 hour at room temperature, and detected by ECL
(PerkinElmer).
qRT-PCR
Total RNA was extracted from the 6 brain regions (right
hemisphere) and spinal cord using the TRIzol/Total RNA
Purification System (Invitrogen). Concentration of RNA was
determined using Nanodrop, and 0.5 ug RNA was converted to
cDNA using the SuperScript III First-Strand Synthesis System
(Invitrogen). Real-time PCR was performed on an ABI7900 using
SYBR green (Applied Biosystems) as the detector. Samples were
run in quadruplicate, with GAPDH used as an endogenous
calibrator for each sample. The SYBR green fluorescent signal was
analyzed using SDS2.2.2 software, and relative quantities of GFPm
were determined.
Stereotaxic surgical procedures
For stereotaxic injections, 1 month old GFPm transgenic mice
were anesthetized with isoflourane (3% for induction, 1.5% for
maintenance) and deemed anesthetized when the corneal eyeblink
and ear-twitch reflexes could no longer be elicited by touch. Mice
were then placed in a Kopf stereotaxic instrument, and the scalp
cleaned with iodine and isopropanol. A midsagittal longitudinal
incision was made in the scalp to expose the skull, and two small
burr holes drilled through the skull (from Bregma, anterior posterior
21.6, mediolateral 61.5, dorsal-ventral 21.5). A 10 mL Hamilton
syringe mounted in an UMP2 Microsyringe injector and Micro4
Pump (World Precision Instruments, Sarasota FL) on the Kopf
apparatus was inserted into the right cortex, and 2 mL of vehicle
(10% DMSO) or MG132 (5 mM in 10% DMSO) injected into the
brain at a flow rate of 0.2 mL/min. The procedure was repeated to
inject vehicle/MG132 into the left cortex. Following the second
injection, Michel clips were used to close the scalp, and mice were
injected with sterile saline for hydration, and placed on a hot pad
under a heating lamp for 2 hours. Mice were also administered
acetaminophen in gelatin ad libitum both pre- and post-operatively
for pain management, and monitored for signs of distress. Mice
were sacrificed by CO2 asphyxiation 24 hours post-injection.
Aseptic techniques were used for all surgical procedures, and all
mouse procedures were performed under an approved IACUC
protocol and in accordance with guidelines established by the NIH.
Supporting Information
Figure S1 No effect of aging on GFP immunolabeling in GFPm
mice. GFP immunoreactivity in cortex (Ctx), midbrain (MID), and
hippocampus (Hipp) from 2 to 18 months of age in heterozygous
GFPm mice. Magnification, 106; inset, 406.
Found at: doi:10.1371/journal.pone.0005888.s001 (15.31 MB
TIF)
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